These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 36453136)

  • 1. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
    Iovino L; Wu QV; Voutsinas J; Panaite L; Mullane E; Lynch RC; Ujjani C; Smith SD; Gopal AK; Till BG; Milano F; Chow V; Gauthier J; Turtle CJ; Maloney DG; Shadman M
    J Cell Mol Med; 2022 Dec; 26(24):5976-5983. PubMed ID: 36453136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
    Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
    Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
    Bachy E; Le Gouill S; Di Blasi R; Sesques P; Manson G; Cartron G; Beauvais D; Roulin L; Gros FX; Rubio MT; Bories P; Bay JO; Llorente CC; Choquet S; Casasnovas RO; Mohty M; Guidez S; Joris M; Loschi M; Carras S; Abraham J; Chauchet A; Drieu La Rochelle L; Deau-Fischer B; Hermine O; Gastinne T; Tudesq JJ; Gat E; Broussais F; Thieblemont C; Houot R; Morschhauser F
    Nat Med; 2022 Oct; 28(10):2145-2154. PubMed ID: 36138152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
    Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
    Riedell PA; Hwang WT; Nastoupil LJ; Pennisi M; McGuirk JP; Maziarz RT; Bachanova V; Oluwole OO; Brower J; Flores OA; Ahmed N; Schachter L; Bharucha K; Dholaria BR; Schuster SJ; Perales MA; Bishop MR; Porter DL
    Transplant Cell Ther; 2022 Oct; 28(10):669-676. PubMed ID: 35850429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
    Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
    Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
    Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
    Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
    Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
    Kwon M; Iacoboni G; Reguera JL; Corral LL; Morales RH; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Domínguez MLG; Pina JMS; Mussetti A; Sancho JM; Bastos-Oreiro M; Catala E; Delgado J; Henriquez HL; Sanz J; Calbacho M; Bailén R; Carpio C; Ribera JM; Sureda A; Briones J; Hernandez-Boluda JC; Cebrián NM; Martin JLD; Martín A; Barba P
    Haematologica; 2023 Jan; 108(1):110-121. PubMed ID: 35770532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
    Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
    Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
    J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
    Bastos-Oreiro M; Gutierrez A; Reguera JL; Iacoboni G; López-Corral L; Terol MJ; Ortíz-Maldonado V; Sanz J; Guerra-Dominguez L; Bailen R; Mussetti A; Abrisqueta P; Hernani R; Luzardo H; Sancho JM; Delgado-Serrano J; Salar A; Grande C; Bento L; González de Villambrosía S; García-Belmonte D; Sureda A; Pérez-Martínez A; Barba P; Kwon M; Martín García-Sancho A
    Front Immunol; 2022; 13():855730. PubMed ID: 35911769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
    Beyar Katz O; Perry C; Grisariu-Greenzaid S; Yehudai-Ofir D; Luttwak E; Avni B; Zuckerman T; Sdayoor I; Stepensky P; Ringelstein-Harlev S; Bar-On Y; Libster D; Sharvit L; Amit O; Greenbaum U; Gold R; Herishanu Y; Benyamini N; Avivi I; Ram R
    Eur J Haematol; 2023 Jul; 111(1):63-71. PubMed ID: 36964939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.